Sanofi: verdict expected

(Boursier.com) — Sanofi camped at 101.25 euros this Thursday, while the group recently received takeover offers concerning its consumer health division from the private equity funds Clayton Dubilier & Rice and PAI Partners. The pharmaceutical group is expected to make a final decision in the coming days on the future of this division after examining these proposals, which could value the entity at 15 billion euros or more…

A year ago, in October 2023, Sanofi announced that it was studying various scenarios for the separation of its consumer division, which notably manufactures Doliprane, via a sale or an IPO. “No decision has been made and we plan to select the best option for Sanofi and its shareholders in the coming months,” said a spokesperson for the group in response to the Bloomberg article. “We are keeping all options open, including a listing and sale, to maximize value creation for all our shareholders,” he added.

Among the latest broker opinions, Deutsche Bank remains for sale with an adjusted target of 85 to 90 euros. Banco Sabadell had already downgraded the file to ‘underweight’ by targeting a price of 113 euros, while Guggenheim had renewed its recommendation to purchase, while adjusting its target to 125 euros. In further support of the case, the United States Food and Drug Administration has approved Dupixent (dupilumab) for the adjunctive maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biological drug approved in the United States for the treatment of this category of patients…